Replies to post #152507 on Biotech Values

[bladerunner1717]

re: ARRY and Selumetinib

Targeting KRAS in lung cancer with a MEK inhibitor


http://pharmastrategyblog.com/2012/11/effectively-targeting-kras-in-lung-cancer-with-a-mek-inhibitor.html/

Sally says this is the first time that she has seen really solid evidence of a MEK inhibitor added to standard chemotherapy in 2nd-line NSCLC that significantly improved overall survival in patients with KRAS mutations.


Bladerunner